Pyoderma gangrenosum - Гангренозум Пиодерма
Гангренозум Пиодерма (Pyoderma gangrenosum) як бемории камёфт ва илтиҳобии пӯст аст, ки дар он пустулҳо ё гиреҳҳои дардовар ба захмҳо мубаддал мешаванд, ки тадриҷан афзоиш меёбанд. гангренозум пиодерма (pyoderma gangrenosum) сирояткунанда нест. Табобат метавонад кортикостероидҳо, циклоспорин ё антителоҳои гуногуни моноклоналиро дар бар гирад. Гарчанде ки он метавонад ба одамони ҳар синну сол таъсир расонад, он бештар ба одамони 40-50-сола таъсир мерасонад.
☆ Дар натиҷаҳои соли 2022 Stiftung Warentest аз Олмон, қаноатмандии истеъмолкунандагон аз ModelDerm нисбат ба машваратҳои пулакии телетиб танҳо каме пасттар буд.
Дар пои шахси гирифтори колити захмдор.
References
Pyoderma gangrenosum як ҳолати нодири пӯст аст, ки боиси захми дарднок бо кунҷҳои сурх ё арғувон мегардад. Он ҳамчун бемории илтиҳобӣ тасниф карда мешавад ва як қисми гурӯҳе мебошад, ки дерматозҳои нейтрофилӣ номида мешаванд. Сабаби pyoderma gangrenosum мураккаб аст, ки мушкилот бо иммунитети модарзод ва мутобиқшавӣ дар одамоне, ки аз ҷиҳати генетикӣ майл доранд. Ба наздикӣ, муҳаққиқон ба фолликулаи мӯй ҳамчун нуқтаи ибтидоии эҳтимолии беморӣ тамаркуз карданд.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum як ҳолати нодири пӯст аст, ки боиси захми ниҳоят дардовар мегардад. Гарчанде ки мо сабаби онро пурра намефаҳмем, мо медонем, ки он афзоиши фаъолияти ҳуҷайраҳои иммунии муайянро дар бар мегирад. Табобати ин беморӣ ҳанӯз осон нест. Мо доруҳои гуногун дорем, ки системаи масуниятро пахш мекунанд ё фаъолияти онро тағир медиҳанд. Дар баробари ин, мо инчунин ба табобати захмҳо ва идоракунии дард диққат медиҳем. Кортикостероидҳо ва циклоспорин аксар вақт интихоби аввалин барои табобат мебошанд, аммо вақтҳои охир дар бораи истифодаи терапевтҳои биологӣ ба монанди ингибиторҳои TNF-α тадқиқоти бештар гузаронида мешавад. Ин биологҳо бештар бартарӣ доранд, махсусан дар беморони гирифтори дигар шароити илтиҳобӣ ва онҳо қаблан дар раванди беморӣ истифода мешаванд.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
